Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of aficamten versus placebo in symptomatic non-obstructive hypertrophic cardiomyopathy
MOH_2024-02-18_013262Phase 3Not yet recruiting
- Sponsor
- Cytokinetics
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on MOH_2024-02-18_013262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-18_013262.